Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.38 |
| ▸ | CA2 | P00918 | 8/20 | 0.38 |
| ▸ | CA12 | O43570 | 5/20 | 0.38 |
| ▸ | CA9 | Q16790 | 5/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10055482 | 0.96 | CA1 (0.36) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL724830 | 0.95 | CA1 (0.40) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL10077804 | 0.90 | CA1 (0.36) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL726171 | 0.86 | PTPN11 (0.42) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL16280908 | 0.82 | DDB1 (0.35) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL10077809 | 0.79 | CA1 (0.41) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL10078808 | 0.78 | CA1 (0.40) | CA1CA2CA12CA9TDP1 | |
| SCHEMBL10077810 | 0.78 | DDB1 (0.33) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL16280909 | 0.77 | PTPN11 (0.35) | CA1CA2CA12CA9PTPN11 | |
| SCHEMBL10077805 | 0.73 | PTPN11 (0.33) | CA1CA2CA12CA9PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9702001-B2 | Scaffold-based polymerase enzyme substrates | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150307933-A1 | SCAFFOLD-BASED POLYMERASE ENZYME SUBSTRATES | PACIFIC BIOSCIENCES CALIFORNIA (US) | 2015-10-29 | — | — | US | disclosed |
| US-8906612-B2 | Scaffold-based polymerase enzyme substrates | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20120077189-A1 | SCAFFOLD-BASED POLYMERASE ENZYME SUBSTRATES | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012027625-A2 | SCAFFOLD-BASED POLYMERASE ENZYME SUBSTRATES | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077189-A1 | SCAFFOLD-BASED POLYMERASE ENZYME SUBSTRATES | POLM, RNGTT, POLR1G | CA1 4803/4885CA2 4370/4885CA12 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.